A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)

• Status: Terminated
• Trial end date: 2014-05-01

Summary

The purpose of this study is to evaluate the efficacy and safety of golimumab (CNTO 148) in patients who have active juvenile idiopathic arthritis (JIA) and at least 5 joints with active arthritis that have poor response to methotrexate.

• Phase: Phase 3

Details

• Lead Sponsor: Janssen Research & Development, LLC
• Collaborator: Schering-Plough
• Treatments: Antibodies, Monoclonal; Golimumab; Methotrexate